Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Clinical trial NCT05455619 · RECRUITING

Trial details

NCT number: NCT05455619
Sponsor: SynDevRx, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HR+/HER2-negative Breast Cancer Metastatic Breast Cancer

Start date: 2022-08-26
Primary completion: 2026-12-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.